Neurocrine Biosciences rated 'Buy' on strong cash flow, key drug Ingrezza, and promising pipeline.

Neurocrine Biosciences is rated a 'Buy' due to its robust cash flows, strong product launches, and a diversified drug pipeline. Its main revenue driver, Ingrezza, holds exclusivity until 2038 with projected peak sales of $3.3 billion. Additional products like Crenessity and Vykat XR contribute to growth. Valuation models suggest the stock is undervalued, supporting a bullish outlook despite conservative assumptions on pipeline potential.